Context Therapeutics is a clinical-stage biopharmaceutical company.
Context Therapeutics has raised $100.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in May 2024.
Context Therapeutics's investors include Blue Owl, Great Point Partners, Blackstone Group, Avidity Partners, Ally Bridge Group.
Context Therapeutics is headquartered in Philadelphia, United States.
Context Therapeutics is a clinical-stage biopharmaceutical company.
Context Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Context Therapeutics — Funding & Investors." VCBacked, May 2, 2024, https://www.vcbacked.co/company/context-therapeutics. Accessed September 30, 2026.
VCBacked. (2024). Context Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/context-therapeutics
{{cite web |title=Context Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/context-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated